Clinical Study
Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
Table 9
Trend of serum CgA values comparing baseline and end-treatment levels are tabulated on the basis of patients’ functional response in the 23/59 cases in which discordant results between CgA trend and 68Ga-peptide PET/CT results were observed.
| |||||||||||||||||||||||||||||||
≤ 10%; *mean variation = 271 220 (range 15–682); variation = 104 119 (range 3–305); §mean variation = 669 ± 554 (range 41–1343). |